Despite Moderna's Boom, Domestic Bio Stocks Slump Amid KOSDAQ Margin Loan 'Empty House' Debate

The KOSDAQ Bio 150 index surged over 8% at one point during the day but then gave back its gains, causing disappointment. Even leading bio stocks such as Alteogen and ST Pharm failed to meet market expectations, indicating that current investor sentiment towards biotech is not positive.

Manager Shin Kwang-sup emphasized investing primarily in stocks with a normal array in the current market. While KOSPI maintains a normal array, KOSDAQ is in a reverse array. He advised focusing on stable normal array stocks rather than chasing short-term spikes in reverse array stocks.

The current lack of liquidity is identified as a major factor limiting the market's buying power. This 'empty house' situation makes it difficult to predict short-term movements in the KOSDAQ market.

There is also a possibility that KOSPI could reach historical highs in the first quarter of next year. For KOSDAQ, he analyzed that an increase in margin loans is essential to break the 900-point mark. At the current margin loan level, there are limits to index growth, suggesting the need for additional liquidity inflow. These index forecasts are expected to be an important basis for investment strategy formulation.

ABL-503 is currently in Phase 2 clinical trials, and the patient cohort has been expanded. Attention is focused on how this data release will affect ABL Bio's stock price.

HLB has an important schedule related to its liver cancer treatment on September 27th. A competitor's liver cancer treatment is expected to receive FDA approval, and analysis suggests that if the competitor is approved, it could cause a short-term shock to HLB's stock price. Additionally, HLB is scheduled to release abstract data at the ESMO conference in October, which is also garnering market attention.

The current market sentiment is focused on obesity, oncology, and vaccine fields, so interest in hair loss treatments is relatively low. However, attention is on whether these data results could be a catalyst for a rebound in Olix's stock price. Investors are expected to closely monitor the data content and market reaction.

Regarding market speculation about a final contract for Peptron on September 7th, Manager Shin Kwang-sup stated that investors should wait until October. The primary reason for Peptron's recent stock price increase is analyzed to be the news of its second plant expansion currently under construction in Osong, Cheongju. Manager Shin recommended a strategy of selling if the stock price surges before a final contract is signed, and buying if it consolidates. This calls for a cautious approach from investors.

D&D Pharmatech was identified as a stock that could rise most sharply if a supply-demand short squeeze occurs. However, there has been no confirmed news regarding a license-out agreement for its key compound, DD01, and currently, only expectations exist. Manager Shin Kwang-sup predicted it could surpass 100,000 won this year but warned that the stock's volatility would be high. Investors should focus on official announcements and approach cautiously. It is pointed out that relying solely on expectations for investment carries significant uncertainty.